Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of inhaled SNG001 for hospitalized adults with moderate COVID-19
MOH_2021-03-09_009742Phase 3Not yet recruiting
- Sponsor
- Synairgen
- Start
- Feb 2021
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing SNG001 with Placebo (2 arms). Primary endpoints: Recovery and Moderate COVID-19 population definition. Planned start Feb 2021; status: not yet recruiting.
02
Drugs
interferon beta-1a
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on MOH_2021-03-09_009742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-03-09_009742.